戻る Agenda
The Science of Compliance
Session Chair(s)
Patrick C. O'Brien, JD, PHARMD
General Counsel
Arrowhead Research Corporation, United States
This forum will discuss how we should be implementing compliance controls in our industry and discuss Codes of Conduct, and the fact that every corporate integrity agreement negotiated between a pharmaceutical or device company and the Office of Inspector General lays out requirements in a way that is probably less likely to be effective than could be.
Learning Objective : Describe how to implement compliance controls into our industry; Discuss how the Office of Inspector General lays out requirements that effects corporate integrity agreements.`
Speaker(s)
The Science of Compliance
Patrick C. O'Brien, JD, PHARMD
Arrowhead Research Corporation, United States
General Counsel
Panelist
Francesca Gino, PHD
Harvard University Business School, United States
Associate Professor, Negotiation, Organization, and Markets Unit
Panelist
Mary Patrice Brown, JD
O'Melveny & Myers LLP, United States
Partner, White Collar Defense and Corporate Investigations Practice